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V entricular assist devices (VADs), because of theirlarge foreign inner surface and heart valves, encour-
age the formation of thrombi, which could become dis-
lodged, enter the circulation, and travel to the various
body tissues with potentially devastating conse-
quences.1 One approach to prevent this problem is the
use of high doses of anticoagulants. However, this tech-
nique has the risk of bleeding complications. Therefore,
biocompatible inner surfaces have been developed for
use in VADs to reduce the tendency for thrombus for-
mation and consequently to enable a reduction of sys-
temic anticoagulation. In the HeartMate left ventricular
assist device (LVAD; Thermo Cardiosystems Inc,
Woburn, Mass), this has been achieved by the creation
of a surface on which a pseudoendothelium layer is
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generated. In the Berlin Heart VAD (Mediport, Berlin,
Germany), the inner surface of the pumps and cannulas
are coated with unfractionated heparins. The coating is
done by the CARMEDA process (Carmeda, Sa, Lund,
Sweden), which has been successfully used for coating
cardiopulmonary bypass (CPB) circuits to reduce con-
tact activation of the coagulation system, the need for
systemic anticoagulation, and the inflammatory
response to the perfusion.2-4 A possible disadvantage of
coating VADs with unfractionated heparins is an
enhanced tendency for the formation of heparin/platelet
factor 4 antibodies (HPF4/A), which have been demon-
strated to play a pivotal role in the pathogenesis of
heparin-induced thrombocytopenia type II (HIT II).5
HIT II is characterized by the induction of antibodies
against complexes of heparin and platelet factor 4. The
newly developed antigen-antibody complex binds to
platelets and initiates a cascade of events, which result
in excessive platelet aggregation that finally leads to
severe thromboembolic complications.6,7
The goal of the present clinical investigation was as
follows:
1. To evaluate whether coating VADs with unfrac-
tionated heparin affects the occurrence of HPF4/A
2. To determine whether this is associated with an
increased risk for the development of thromboem-
bolic complications, in particular on coated sur-
faces, in these patients.
Methods
Devices. The Berlin Heart VAD consists of a polyurethane
blood pump that is coated with unfractionated heparins
(Carmeda). Each pump carries 2 mechanical heart valves and
is connected by 2 silicone cannulas. The Berlin Heart system
can be used for both single ventricular and biventricular assis-
tance. The LVAD (Baxter Healthcare Corp, Oakland, Calif) is
made of polyurethane and connected by Dacron inflow and
outflow tracts. It contains biologic heart valves. The TCI
HeartMate LVAD chamber (Thermo Cardiosystems) is made
of titanium with a rough inner layer, which permits the gen-
eration of a natural pseudoendothelium. The DeBakey LVAD
(Micromed Technology, the Woodlands, Tex) generates a
laminar flow by a rotary blood pump and uses a valveless
Dacron outflow graft.
Groups of patients. After approval by the local ethics
committee and informed consent, 100 patients who received
a VAD in our institution from 1995 to 1999 were enrolled in
the investigation. The investigation was performed by using
deep-frozen samples, which were collected during hospital-
ization of the patients. The decision to implant an LVAD or a
biventricular assist device system was based on clinical
necessity (cardiogenic shock and severe right heart failure). A
Berlin Heart system was implanted if the patient needed
biventricular assistance. A solely left ventricular Berlin Heart
system was planted via a left thoracotomy in patients who had
undergone median sternotomy previously. Patients were
divided into 2 groups. Group 1 consisted of patients with a
heparin-coated VAD (Berlin Heart system), and group 2 con-
sisted of patients with a noncoated VAD (other systems).
Anticoagulation protocol. Before the operation, anticoag-
ulation was switched to unfractionated heparin (UFH;
Liquemin) to achieve a target activated partial thromboplas-
tin time value between 40 and 60 seconds. Anticoagulation
during implantation with the use of CPB was accomplished
with UFH according to the Hepcon HMS (Medtronic
HemoTec, Inc, Englewood, Colo; E. M. Parker Company,
Inc, Wilmington, Mass). After termination of CPB, the anti-
coagulant effect of heparin was reversed with protamine sul-
fate (Hoffmann-La Roche Ltd, Basel, Switzerland).
Intravenous heparinization was restarted 6 to 12 hours after
the operation to achieve a target activated clotting time of 160
to 180 seconds. Antiplatelet agents were simultaneously
administered on the basis of the results of the in vitro platelet
aggregation tests. The tests were performed with 20 µmol/L
adenosine diphosphate, 100 µL/L epinephrine, 190 µg/mL
collagen, and 500 µg/mL arachidonic acid. The target value
for adenosine diphosphate– and epinephrine-induced platelet
aggregation was 30% to 50% and less than 40% for arachi-
donic acid-induced aggregation. A decrease of the aggrega-
tion to a value of 70% to 90% was regarded as sufficient for
collagen-induced platelet aggregation. Antiplatelet therapy
was initiated with aspirin, beginning with 50 mg/d up to 200
mg/d as a maximum dose. If patients did not respond to this
therapy, dipyridamole (400-1000 mg/d) was given.
After removal of all drainage tubes, patients with the Berlin
Heart, Novacor, and DeBakey LVADs were switched to war-
farin sodium and aspirin, depending on the results of the
platelet function test. Patients on the TCI system were treat-
ed with aspirin only. Heparinization was only re-established
in cases of an increased risk for thrombus formation (immo-
bilization, parameters of infection as demonstrated by white
blood cell count, and measurement of C-reactive protein) and
a tendency for hyperaggregation in the platelet aggregation
assay, which did not respond to antiplatelet therapy.
Detection of thromboembolism. Thromboembolism was
confirmed or excluded by computed tomography, angiogra-
phy, and Doppler ultrasonography after clinical suspicion. In
the Berlin Heart VAD the pumps are placed outside the
patient, and because they are transparent, visual examination
of the pumps for thrombus formation was performed daily.
Thrombus formation was regarded as recurrent if they were
found in the pumps on more than 3 occasions during the 3-
month period of the investigation.
Detection of HPF4/A. Blood samples were collected
before implantation, on the seventh and fourteenth postoper-
ative days, and 3 months later. The samples were tested by the
use of the ASSERCHROM HPIA enzyme immunoassay
(Diagnostica Stago, Asnierssur-Seine, France). The results
were considered positive if an optical density of greater than
0.480 was found at an absorbency level of 492 nm.
Platelet count and heparin-induced platelet aggregation
assay. The platelet count was performed daily. The heparin
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platelet aggregation assay (HIPAA)8 was performed if the
patient had a postoperative platelet count of less than
100,000/mL that failed to recover within 2 days or if a patient
had a decrease in the platelet count of greater than
30,000/mL. The HIPAA result was deemed positive when
agglutination was observed in 2 of 4 chambers with 0.2
IU/mL heparin and a negative result in the buffer and the 100
IU/mL heparin chambers. In patients who had positive test
results for HIT II according to the HIPAA, further anticoagu-
lation was performed with recombinant hirudin (Refludan),
with a target activated partial thromboplastin time value of 40
to 60 seconds.9
Statistical analysis. Statistical analyses of the data were
performed with SPSS 7.5 for Windows (SPSS, Inc, Chicago,
Ill). Significant differences were confirmed by the Student t
test (for continuous data). Qualitative variables were ana-
lyzed by the χ2 test.
Results
There were no significant differences in the biomet-
ric data, parameters of infection, and duration of
heparinization for the 2 groups. Fifty-five patients
belonged to group 1 and 45 to group 2. There were 64
male and 36 female patients, with ages ranging from 18
to 64 years (mean ± SD, 47 ± 10 years). In 63 patients
the implantation of the device was necessary because
of dilated cardiomyopathy, in 5 because of restrictive
cardiomyopathy, in 7 because of acute myocarditis, and
in 25 because of ischemic cardiomyopathy. In 51
patients the implantation of a biventricular assist device
(Berlin Heart) was necessary. Forty-nine patients
received an isolated LVAD (30 Novacor, 7 TCI, 6
Berlin Heart, and 6 DeBakey VAD).
Prevalence and persistence of HPF4/A. In group 1,
32 patients had positive test responses for HPF4/A (21
before the operation), whereas in group 2, 31 patients
had positive test results for HPF4/A (25 before the
operation, P = .102). No patient had positive results for
HPF4/A after discontinuation of heparin treatment.
Fourteen patients from group 1 and 18 patients from
group 2 had negative results for HPF4/A after discon-
tinuation of heparin. Thirteen patients from group 1
and 14 patients from group 2 continued to have positive
results for HPF4/A after discontinuation of heparin.
There were no significant differences in the prevalence
and persistence of HPF4/A between the 2 groups.
HPF4/A and embolism. Embolic events (cerebral
infarction, mesenteric infarction, pulmonary em-
bolism, and peripheral embolization of the extremi-
ties) were identified in 10 patients with positive
results for HPF4/A in group 1 and 12 with positive
results in group 2. There were no thromboembolic
events in patients with negative results for HPF4/A.
Twenty-two patients in group 1 and 19 in group 2
with negative results for HPF4/A had no occurrence
of emboli. There were no significant differences
between the 2 groups.
Recurrent pump thromboses and HPF4/A in
heparin-coated VADs. In group 1, 11 patients with
positive results for HPF4/A and 9 patients with nega-
tive results for the antibody exhibited at least 3 repeti-
tive thrombi in the pump. There was no significant dif-
ference between the occurrence of repetitive pump
thrombus formation for patients with positive and neg-
ative HPF4/A results. Twenty-one patients with posi-
tive results for HPF4/A had no repetitive thrombus for-
mation in the pump.
Platelet count and HIPAA. The HIPAA was per-
formed in 13 patients: 7 from the coated group and 6
from the noncoated group. Three of these patients had
a positive reaction, and in all of these, HPF4/A was
detectable in the enzyme-linked immunosorbent assay.
One of these 3 patients demonstrated no clinical symp-
toms of thromboembolism, 1 had a stroke caused by
embolization, and the third had acute Leriche syn-
drome. Three of the 10 patients with a negative HIPAA
result had positive results for HPF/4A. There were no
significant differences in platelet count and HIPAA for
groups 1 and 2.
Discussion
The main findings from our study were that heparin
coating of the VAD surface does not enhance HPF4/A-
associated immunologic or thrombogenic reactions.
However, the presence of these antibodies is strongly
associated with an increased risk of thromboembolism
in patients with a VAD. This is of great importance in
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Table I. HPF4/A in heparin-coated and noncoated
VADs
Heparin-coated Noncoated
Patient total 57 43
Positive results 32 31
First day positive 21 25
Became positive after intravenous 
heparin stopped 0 0
Became negative after intravenous
heparin stopped 14 18
Table II. HPF4/A and thromboembolism
Heparin-coated Noncoated
Positive with TE 10 12
Positive without TE 22 19
Negative without TE 0 0
TE, Thromboembolism.
view of the comparably high prevalence (63%) of anti-
bodies in these patients.
HPF4/A plays a pivotal role in HIT II and in the for-
mation of heparin-associated thromboemboli. Large dif-
ferences have been described in the incidence of these
antibodies in patients who undergo different types of
operations. Bauer and associates10 found HPF4/A in
19% of patients before and 51% after cardiac operations,
whereas Trossaért,11 Pouplard,12 and their colleagues
found it in 27% and 25.3% of patients, respectively, after
cardiac operations. Visentin and coworkers13 described
an incidence of HPF4/A of 61% after cardiac opera-
tions and 4.5% after noncardiac operations; they
reported no HPF4/A in patients who did not have oper-
ations. Jackson and associates14 reported an incidence
of HPF4/A in 2% of patients who underwent vascular
operations. The large fraction of patients who revealed
HPF4/A before operations in the present study may be
explained by multiple hospitalizations and exposures to
heparin before the need for implantation of a VAD.
In our study only patients with positive results for
HPF4/A had thromboemboli and clinical symptoms of
HIT II. Thus the presence of such antibodies may be
regarded as a predictor of an increased risk for the
development of thromboembolic complications.
Several findings from this study suggest that coating
of the inner surface of VADs with unfractionated
heparins does not lead to an immunization against
heparins. First, no patient from group 1 (the coated
group) had antibodies after reversal of systemic
heparinization. Second, there was no difference in the 2
groups in the number of patients whose results became
antibody negative after the termination of systemic
heparinization or in the incidence of thromboembolic
complications. Furthermore, circulating antibodies
seemed not to induce thrombus formation on the
heparinized surface because there was no difference in
the incidence of repetitive pump thrombi between
patients with a positive antibody status when compared
with patients with a negative status in the heparin-coat-
ed group. These clinical data are consistent with the
results of recent laboratory investigations, which
revealed that HPF4/A does not bind to platelet factor 4
complexed with heparin immobilized by multiple
chemical cross linkages.15 However, further investiga-
tions to prove whether this also applies for other
Carmeda-coated materials, such as CPB systems or
catheters, are required.
In conclusion, we found that patients with a VAD
have a high incidence of HPF4/A. These antibodies
were strongly associated with an increased risk of
development of thromboembolic complications, and
the frequency of these complications was independent
of whether the inner surface of VAD was coated with
heparin. Further investigations are necessary to clarify
the precise role played by the HPF4/A in thrombus and
embolus formation.
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